NIH Invents Omega-3 Boosted Cancer Vaccines
Published Date: 6/25/2026
Notice
Summary
The National Cancer Institute has created a new way to make cancer vaccines stronger by using special omega-3 fats to boost immune cells called dendritic cells. This could help scientists and companies develop better cancer treatments that work more effectively. If you’re in biotech or medicine, now’s the time to team up or license this exciting technology and help bring improved vaccines to patients faster.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
NCI Offers Licensing for Omega‑3 DC Vaccine Tech
The National Cancer Institute is offering its compositions and methods that use omega‑3 fatty acids (DHA and EPA) or pro‑resolving lipid mediators to boost dendritic cell (DC) cancer vaccine effectiveness for licensing or co‑development. The technology is at a pre‑clinical stage (in vivo validation), has NIH reference number E-231-2023, and a PCT patent was filed on September 27, 2024 (PCT/US2024/049057). NCI is actively seeking research partners and licensees to develop these therapeutic oncology applications.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12843 — Government Owned Inventions Available for License: C8166-45 Cell Line
The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!
2026-12844 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings on July 17, 2026, to review important grant applications. These meetings protect private info and trade secrets while deciding which science projects get funding. Researchers applying for grants in brain injury, neurobehavior, nanotech, and heart/lung studies should note these review dates and prepare accordingly.
2026-12565 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for cool science projects. If you’re a researcher waiting on grants, these reviews shape the future of your funding and the science world!
2026-12585 — Submission for OMB Review; 30-Day Comment Request; Chimpanzee Research Use Form (Office of the Director)
The NIH wants to keep collecting info using the Chimpanzee Research Use Form and is asking the public to share thoughts by July 23, 2026. This form helps track how chimpanzees are used in research, affecting scientists and animal welfare groups. No big changes or costs are expected, just a smooth extension of the current form’s approval.
2026-12244 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide funding for health research projects. Scientists and researchers applying for grants should note these dates as they impact which projects get money.
2026-12116 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important grant applications. These meetings protect private info and trade secrets while helping fund research on mice, drug development, and primate centers. Scientists and research groups applying for grants should watch for these dates as they impact funding decisions.
Previous / Next Documents
Previous: 2026-12835 — Agency Information Collection Activities; Notice and Request for Comment; Intelligent Speed Assistance (ISA) User Acceptance and Effectiveness Testing Using Simulator and/or Closed Track Methods
The National Highway Traffic Safety Administration (NHTSA) wants to study how drivers feel about and use Intelligent Speed Assistance (ISA) technology by testing it in simulators and closed tracks. They’re asking the public to share their thoughts before August 24, 2026. This helps make sure the new info collection is useful and won’t waste anyone’s time or money.
Next: 2026-12843 — Government Owned Inventions Available for License: C8166-45 Cell Line
The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!